Statin use among older women may increase DM risk
Older women who use statins may be at an increased risk for diabetes mellitus (DM), according to the results of a study published online January 9 in the Archives of Internal Medicine.
The results of this study imply that statin use may increase risk of new-onset DM in postmenopausal women and that potency or individual statin may not play a role, according to lead study author Annie L. Culver, BPharm, Divisions of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, Mass., and colleagues.
The authors examined statin use among postmenopausal women participating in the Women's Health Initiative (WHI), which recruited 161,808 postmenopausal women aged 50 to 79 years at 40 US clinical centers between 1993 and 1998 with ongoing follow-up. The investigators used WHI data through 2005 for a total of 153,840 women who had not been diagnosed with DM and with no missing data at baseline.
A total of 7.04% of the patients reported taking a statin medication. Researchers found statin use at baseline was associated with an increased risk of DM (HR=1.71; 95% CI, 1.61–1.83), and the association remained consistent after adjusting for other potential confounders (HR=1.48; 95% CI, 1.38–1.59) and was observed for all types of statin medications.
“The consequences of statin-induced DM have not been specifically defined and deserve more attention,” the authors wrote. “Given the wide use of statins in the aging population, further studies among women, men, and diverse ethnicities will clarify DM risk and risk management to optimize therapy.”
MORE ARTICLES IN THIS ISSUE
Aspirin prophylaxis in people without prior cardiovascular disease does not appear to reduce cardiovascular death or cancer mortality, according to the results of a meta-analysis published online January 9 in the Archives of Internal Medicine.
FDA approved ingenol mebutate (Picato, LEO Pharma) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). It is the first topical AK therapy that can be used for as few as 2 or 3 consecutive days.
The Endocrine Society recently released new clinical practice guidelines recommending that all patients have their blood-glucose levels tested upon admission to the hospital, even if they haven’t been diagnosed with diabetes.
FDA recently announced that a clinical trial evaluating the effects of doripenem (Doribax, Janssen) on the treatment of patients with ventilator-associated pneumonia was halted because of an increase in death rate and a poor clinical cure rate.
FDA and Seattle Genetics, which makes brentuximab vedotin (Adcetris), have updated the warning label on the company’s cancer drug after a second patient developed progressive multifocal leukoencephalopathy.